Bulletin
Investor Alert

New York Markets After Hours

Market Pulse Archives

Dec. 3, 2021, 3:00 p.m. EST

Lilly's COVID-19 antibody treatment authorized for young children and infants

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eli Lilly & Co. (LLY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY +1.21% were down 1.6% in trading on Friday after the company said the Food and Drug Administration has extended the emergency authorization for its COVID-19 antibody therapy to include children younger than 12 years old. This is the first authorization for a monoclonal antibody treatment for infants and children. Lilly said the therapy can now be used in high-risk children as a treatment or for post-exposure prophylaxis. The company also said that more than 700,000 patients have been treated with bamlanivimab or a combination of bamlanivimab and etesevimab. Lilly's stock is up 44.5% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -1.84% has gained 21.6%.

/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 247.07
+2.95 +1.21%
Volume: 3.24M
Jan. 18, 2022 4:03p
P/E Ratio
37.72
Dividend Yield
1.59%
Market Cap
$233.52 billion
Rev. per Employee
$793,100
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,577.11
-85.74 -1.84%
Volume: 2.74B
Jan. 18, 2022 4:56p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.